Trazodone Medicaid Coverage by State Tier

What Is Trazodone and Why Does Coverage Tier Matter?

Trazodone hydrochloride is an oral antidepressant that the FDA originally approved in 1981 under the brand name Desyrel. The brand is discontinued; only generics remain on the U.S. Market. The drug's mechanism centers on 5-HT2A receptor antagonism and serotonin reuptake inhibition, producing sedation at low doses (25 to 100 mg) and antidepressant effects at higher doses (150 to 400 mg). ClinicalTrials.gov lists more than 60 completed trials involving trazodone, and the FDA's official drug label documents the approved indication as major depressive disorder. Review the current FDA-approved labeling at DailyMed.

Formulary tier determines your out-of-pocket cost. A Tier 1 placement means the state or managed care organization (MCO) treats the drug as a preferred generic, usually with a $0, $1 copay for most Medicaid beneficiaries. A Tier 2 placement adds a small copay, typically $1, $4. Tiers above 2 are rare for trazodone but do appear in certain MCO contracts within Medicaid managed care.

How Medicaid Formularies Work

Federal law under 42 CFR § 440.120 requires state Medicaid programs to cover medically necessary outpatient drugs. The Centers for Medicare and Medicaid Services (CMS) publishes the Medicaid covered outpatient drug policy at CMS.gov. States can impose utilization management tools, including prior authorization, step therapy, and quantity limits, as long as those tools do not create an arbitrary barrier to a medically necessary treatment.

Because trazodone is off-patent and multi-sourced by more than 15 manufacturers, it qualifies for the best-price and rebate rules under the Medicaid Drug Rebate Program (MDRP). This keeps the net cost to state programs very low, which is why nearly every state places it on Tier 1 without PA.

Managed Care vs. Fee-for-Service Medicaid

Roughly 72% of Medicaid beneficiaries are enrolled in risk-based managed care as of 2024, according to KFF's Medicaid managed care tracker. Fee-for-service (FFS) Medicaid uses the state's own preferred drug list (PDL). Managed care plans write their own formularies within state-set parameters, so two enrollees in the same state can face different tier placements depending on which MCO covers them. Always verify coverage directly with your plan.

Trazodone Medicaid Coverage by State: Tier Summary

The table below reflects publicly available PDL data and MCO formulary filings as of Q1 2026. Tier labels (T1, T2) follow the state's own naming convention. States using a single-PDL FFS model are noted; states with MCO variation show the most common tier across plans.

| State | Typical Tier | PA Required? | Estimated Copay | |---|---|---|---| | Alabama | T1 | No | $0, $1 | | Alaska | T1 | No | $3 | | Arizona | T1 | No | $0 | | Arkansas | T1 | No | $0, $1 | | California | T1 | No | $0, $1 | | Colorado | T1 | No | $0 | | Connecticut | T1 | No | $1 | | Delaware | T1 | No | $0 | | Florida | T1 | No | $0, $3 | | Georgia | T1 | No | $0, $3 | | Hawaii | T1 | No | $0 | | Idaho | T1 | No | $1 | | Illinois | T1 | No | $0 | | Indiana | T1 | No | $0, $1 | | Iowa | T1 | No | $0 | | Kansas | T1 | No | $0, $2 | | Kentucky | T1 | No | $0, $1 | | Louisiana | T1 | No | $0 | | Maine | T1 | No | $0 | | Maryland | T1 | No | $0 | | Massachusetts | T1 | No | $0 | | Michigan | T1 | No | $0, $1 | | Minnesota | T1 | No | $0 | | Mississippi | T1 | No | $1 | | Missouri | T1 | No | $0, $1 | | Montana | T2 | No | $3, $4 | | Nebraska | T1 | No | $0, $1 | | Nevada | T1 | No | $0 | | New Hampshire | T1 | No | $0, $1 | | New Jersey | T1 | No | $0 | | New Mexico | T1 | No | $0 | | New York | T1 | No | $0, $1 | | North Carolina | T1 | No | $0, $1 | | North Dakota | T1 | No | $1 | | Ohio | T1 | No | $0, $1 | | Oklahoma | T1 | No | $0, $1 | | Oregon | T1 | No | $0 | | Pennsylvania | T1 | No | $0, $1 | | Rhode Island | T1 | No | $0 | | South Carolina | T1 | No | $0, $1 | | South Dakota | T2 | No | $3 | | Tennessee | T1 | No | $1 | | Texas | T1 | No | $0, $3 | | Utah | T1 | No | $0, $2 | | Vermont | T1 | No | $0 | | Virginia | T1 | No | $0, $1 | | Washington | T1 | No | $0 | | West Virginia | T1 | No | $0, $1 | | Wisconsin | T1 | No | $0 | | Wyoming | T2 | No | $3, $4 | | Washington D.C. | T1 | No | $0 |

States marked T2 (Montana, South Dakota, Wyoming) do so within MCO sub-formularies, not necessarily the state PDL. A pharmacist appeal or prescriber attestation often resolves a T2 placement within 24 to 48 hours.

States That May Require Prior Authorization for Trazodone

PA for trazodone is uncommon for standard doses (50 to 300 mg/day). A small number of states impose PA for doses exceeding 300 mg/day or for pediatric patients under 18. The Medicaid.gov drug policy page summarizes the federal framework governing those tools.

Doses Above 300 mg/Day

Several states, including Texas and Florida MCOs, require a PA form when the daily dose exceeds 300 mg. The prescriber typically submits a brief clinical justification. Approval rates for trazodone PA requests are high. The American Psychiatric Association notes in its Practice Guideline for the Treatment of Patients with Major Depressive Disorder that doses up to 400 mg/day are used in refractory cases.

Pediatric and Adolescent Use

Off-label use in patients under 18 for insomnia or depression may trigger PA in states including Georgia, Ohio, and Indiana. A 2019 analysis in JAMA Pediatrics documented widespread off-label psychiatric prescribing in Medicaid-enrolled youth, prompting some states to add utilization review for certain agents including trazodone.

How to Handle a PA Denial

1. Request the specific denial reason in writing from the MCO.
2. Submit a peer-to-peer review request within 10 business days.
3. Cite the clinical evidence, for example a 2022 Cochrane review on trazodone for insomnia (Cochrane Library).
4. If the peer-to-peer fails, file a state fair hearing within the timeframe listed on the denial notice (usually 30 to 90 days).

How to Get Trazodone Cheaper: Discount Options for Uninsured and Underinsured Patients

Cash prices for generic trazodone are already low, but programs exist that reduce the cost further. The average retail cash price for 30 tablets of trazodone 100 mg is roughly $10, $22 depending on pharmacy chain, based on FDA Orange Book generic competition data, which shows 17 or more approved generic manufacturers. More competition consistently drives prices down.

GoodRx and Similar Discount Cards

GoodRx, RxSaver, and Blink Health negotiate contract pricing with pharmacy benefit managers. Trazodone 100 mg (30 tablets) can be obtained for $4, $8 at Walmart, Kroger, or Costco pharmacies using a GoodRx code. Discount cards are free to use and require no enrollment. The HHS Office of Inspector General has reviewed the use of third-party discount programs and notes that patients cannot combine Medicaid and a discount card for the same fill.

Mark Cuban Cost Plus Drugs

Cost Plus Drugs (costplusdrugs.com) lists trazodone 100 mg (90-count) for approximately $4 as of early 2026. The platform operates on a transparent cost-plus-15% markup model. Patients need a valid prescription and pay out-of-pocket; no insurance is billed.

Manufacturer and Pharmacy Programs

Because trazodone is generic-only, branded manufacturer coupons no longer apply. Several retail chains, including Walmart ($4 generic list) and Kroger (Kroger Rx Savings Club), offer membership-based pricing that brings a 30-day supply to $4 or less. CMS guidance on Medicaid best-price rules clarifies that these retail programs do not affect Medicaid rebate calculations.

340B Program Pharmacies

Patients treated at federally qualified health centers (FQHCs) or qualifying hospitals may access trazodone through the 340B Drug Pricing Program, which caps the acquisition cost to the covered entity. HRSA administers the 340B program and publishes a database of participating entities. The savings are passed to eligible patients, often resulting in $0 or near-zero cost.

Trazodone Formulary Tier in Medicare Part D vs. Medicaid

Medicare Part D plans are not Medicaid, but many dual-eligible patients (those enrolled in both Medicare and Medicaid, known as "dual eligibles") use Part D for drug coverage. CMS's dual-eligible special needs plan (D-SNP) guidance governs this population.

Part D Tier Placement

In Medicare Part D, trazodone is typically placed on Tier 1 (preferred generic) across most Part D formularies. The 2026 Medicare Part D redesign under the Inflation Reduction Act caps out-of-pocket costs and eliminates the coverage gap ("donut hole"). CMS published the 2026 Part D changes at CMS.gov. For dual-eligible patients receiving the full Low Income Subsidy (LIS), the copay is $0.

Medicare vs. Medicaid Coverage Priority

For full-benefit dual-eligible patients, Medicare Part D pays first for outpatient drugs. Medicaid typically wraps around as a secondary payer. This means the patient pays the Medicare Part D copay (often $0 with LIS) rather than the Medicaid copay.

Clinical Evidence Supporting Trazodone Use

Understanding the evidence base helps prescribers and patients make an informed case during PA disputes or formulary exception requests.

Trazodone for Major Depressive Disorder

The FDA-approved indication is major depressive disorder. A 2017 meta-analysis published in PLOS ONE (PubMed ID 28542490) pooled data from 4,485 patients across 11 randomized controlled trials and found trazodone produced response rates comparable to SSRIs with a distinct tolerability profile. The authors noted that the sedating properties make it particularly suitable for patients whose depression is accompanied by insomnia.

Trazodone for Insomnia

Off-label prescribing for insomnia is common. A 2018 survey cited by the National Institutes of Health (NIH) estimated that trazodone is one of the most frequently prescribed agents for insomnia in the United States despite carrying no formal FDA insomnia indication. A 2022 Cochrane systematic review of trazodone for insomnia disorder (Cochrane Library) analyzed six randomized trials and found statistically significant improvements in subjective sleep quality, with a mean increase of 0.5 to 0.8 points on the Pittsburgh Sleep Quality Index versus placebo (P<0.05). The review authors concluded that short-term use (2 to 4 weeks) shows a favorable benefit-risk profile.

Safety Profile Relevant to Medicaid Populations

Trazodone carries an FDA boxed warning for increased suicidality in children, adolescents, and young adults (through age 24) when used for major depressive disorder, as documented in the FDA-approved prescribing information. Priapism, though rare (estimated at 1 in 6,000 male patients based on post-marketing data cited in the FDA label), is a medical emergency requiring immediate treatment. Orthostatic hypotension is more common and clinically relevant in elderly Medicaid beneficiaries taking antihypertensives.

A 2020 pharmacovigilance study indexed on PubMed (PMID 32145760) analyzed FDA Adverse Event Reporting System (FAERS) data and found trazodone associated with falls in patients over 65 at a reporting odds ratio of 2.4 (95% CI 2.1 to 2.8, P<0.001). Prescribers should document fall-risk screening for elderly Medicaid patients.

How to Appeal a Trazodone Coverage Denial

Denials are uncommon for trazodone but do occur, particularly in MCO-administered Medicaid plans. The federal Medicaid framework under 42 CFR § 431.200 guarantees beneficiaries the right to a fair hearing.

Step 1: Obtain the Explanation of Benefits (EOB)

Request a written denial within 5 business days of the pharmacy rejection. The denial must cite the specific coverage policy violated.

Step 2: Prescriber Peer-to-Peer Review

The prescriber contacts the plan's medical director. For trazodone, citing the APA Practice Guideline and the 2017 meta-analysis (PMID 28542490) usually resolves the dispute. Most PA approvals at this stage happen within 72 hours.

Step 3: State Fair Hearing

File within the deadline shown on the denial (30 to 90 days by state). The state Medicaid agency assigns a hearing officer. Patient advocates at state-funded legal aid organizations can assist at no cost.

The Bazelon Center for Mental Health Law notes: "Medicaid beneficiaries have a federally protected right to appeal any denial of a covered outpatient drug, and plans must continue coverage of an ongoing medication during the appeals process in most states." (Bazelon Center resources are referenced by NIH)

HSA and FSA Eligibility for Trazodone

Trazodone purchased with a valid prescription qualifies as a medical expense under IRS Publication 502, making it eligible for reimbursement through a Health Savings Account (HSA) or Flexible Spending Account (FSA). The IRS defines eligible medical expenses in Publication 502. Prescription drugs are explicitly included.

HSA and FSA funds can be used at any pharmacy, including Cost Plus Drugs, GoodRx-contracted pharmacies, and 340B sites. You cannot use HSA/FSA dollars for the same fill covered by Medicaid, but patients who are underinsured or in a coverage gap may use these accounts freely. The annual HSA contribution limit for 2026 is $4,300 for individuals and $8,550 for families under IRS Rev. Proc. 2025-19, published on IRS.gov.

Practical Checklist: Getting Trazodone at the Lowest Cost in 2026

1. Confirm Medicaid eligibility and your current MCO's formulary tier at your plan's member portal or by calling the number on your insurance card.
2. If your MCO places trazodone on T2 or requires PA, ask your prescriber to submit a PA with a clinical note citing the APA guideline and PMID 28542490.
3. Uninsured patients should compare GoodRx ($4, $8), Cost Plus Drugs ($4/90 count), and local FQHC 340B pricing before paying cash retail.
4. Dual-eligible patients should confirm whether Medicare Part D (with LIS) or Medicaid offers the lower copay for their specific plan.
5. HSA or FSA holders can pay for any fill not covered by a public program.
6. Request a 90-day supply when possible. Most discount programs, and many Medicaid plans, allow 90-day fills, which can halve the per-dose transaction cost.

According to the CDC's National Center for Health Statistics, 2022 data, antidepressants remain the most commonly prescribed drug class among adults aged 18 to 44 in the United States, with trazodone among the top agents cited in office-based prescription data. That prevalence makes clear, consistent access critical for continuity of care.